open access publication

Article, 2024

Evaluation of the clinical significance of long non-coding RNA MALAT1 genetic variants in human lung adenocarcinoma

Aging, ISSN 1945-4589, Volume 16, 6, Pages 5740-5750, 10.18632/aging.205675

Contributors

Lin, Shu-Hui [1] [2] [3] Lu, Jeng-Wei 0000-0003-2128-2046 [4] Hsieh, Wang-Ting [5] [6] Chou, Ying-Erh [7] Su, Tzu-Cheng [3] Tsai, Tun-Jen [6] Tsai, Yun-Jung [3] Yang, Po-Jen (Corresponding author) [7] [8] Yang, Shun-Fa (Corresponding author) [7] [8]

Affiliations

  1. [1] Central Taiwan University of Science and Technology
    2. [NORA names: Taiwan; Asia, East];
  2. [2] National Chung Hsing University
    3. [NORA names: Taiwan; Asia, East];
  3. [3] Changhua Christian Hospital
    4. [NORA names: Taiwan; Asia, East];
  4. [4] University of Copenhagen
    5. [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD];
  5. [5] Asia University
    6. [NORA names: Taiwan; Asia, East];

Abstract

Lung adenocarcinoma (LUAD) is the most frequent histological subtype of lung cancer, which is the most common malignant tumor and the main cause of cancer-related mortality globally. Recent reports revealed that long non-coding RNA (lncRNA) of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) plays a crucial role in tumorigenesis and metastasis development in lung cancer. However, the contribution of MALAT1 genetic variants to the development of LUAD is unclear, especially in epidermal growth factor receptor (EGFR) mutation status. In this study, 272 LADC patients with different EGFR status were recruited to dissect the allelic discrimination of the MALAT1 polymorphisms at rs3200401, rs619586, and rs1194338. The findings of the study showed that MALAT1 polymorphisms rs3200401, rs619586, and rs1194338 were not associated to LUAD susceptibility; however, rs3200401 polymorphisms was significantly correlated to EGFR wild-type status and tumor stages in LUAD patients in dominant model (p=0.016). Further analyses using the datasets from The Cancer Genome Atlas (TCGA) revealed that lower MALAT1 mRNA levels were associated with the advanced stage, and lymph node metastasis in LADC patients. In conclusion, our results showed that MALAT1 rs3200401 polymorphisms dramatically raised the probability of LUAD development.

Keywords

Atlas, Cancer Genome Atlas, EGFR wild-type status, Genome Atlas, LADC, RNA, TCGA, adenocarcinoma, advanced stage, allelic discrimination, analysis, cancer, cancer-related mortality, clinical significance, contribution, dataset, development, development of lung adenocarcinoma, discrimination, dominant model, epidermal growth factor receptor, epidermal growth factor receptor status, evaluation, factor receptor, findings, genetic variants, growth factor receptor, histological subtypes, histological subtypes of lung cancer, human lung adenocarcinoma, levels, lncRNAs, long non-coding RNAs, lung, lung adenocarcinoma, lung adenocarcinoma patients, lung adenocarcinoma transcript 1, lung cancer, lymph, lymph node metastasis, mRNA, mRNA levels, malignant tumors, metastasis, metastasis development, metastasis-associated lung adenocarcinoma transcript 1, model, mortality, mutation status, mutations, node metastasis, non-coding RNAs, patients, polymorphism, probability, receptors, reports, results, rs1194338, rs3200401, stage, status, study, subtype of lung cancer, susceptibility, transcript 1, tumor, tumor stage, tumorigenesis, variants, wild-type status

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+